NEW YORK – Tune Therapeutics on Sunday said it has raised more than $175 million in a Series B funding round, which it will use to support its epigenome-editing hepatitis B program and advance its gene-tuning platform.
The Series B round was led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation.
Tune, which has offices in Seattle and Durham, North Carolina, will use the funding to accelerate development of its existing pipeline, including its lead program Tune-401, which recently began testing within clinical trials in New Zealand and Hong Kong. Tune-401 is an epigenetic silencing drug for chronic hepatitis B.
Tune-401 uses the company's gene-tuning platform, TEMPO, to silence and repress both viral hepatitis B DNA that has integrated into the host genome and covalently closed circular DNA that contributes to viral infection. The TEMPO platform uses epigenetic editing, so it does not require cutting, damaging, or altering genomic DNA sequences, according to Tune.
"With this renewed support, we are well positioned to advance our HBV clinical program, to invest in our platform, and to expand our pipeline," Tune CFO, President, and Cofounder Akira Matsuno said in a statement.